Human Trials

Merck and Pfizer’s SGLT2 inhibitor STEGLATRO meets primary endpoint in VERTIS CV trial

Merck, known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced the presentation of results from the Phase 3 VERTIS CV cardiovascular (CV) outcomes trial that evaluated STEGLATRO (ertugliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, versus placebo, added to background standard of care treatment, in more than 8,200 patients with type 2 diabetes and atherosclerotic CV disease across 531 centers in 34 countries.

SC formulation of DARZALEX combination delivers deep and rapid haematologic responses and improved clinical outcomes in newly diagnosed light chain amyloidosis

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomised Phase 3 study investigating the subcutaneous (SC) formulation of DARZALEX (daratumumab) in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.

Eli Lilly commences Covid-19 study with oral JAK1/JAK2 inhibitor baricitinib

Eli Lilly has commenced a phase 3 clinical trial with baricitinib, marketed as Olumiant, for hospitalised Covid-19 patients.

Cannabinoid Purification and Scale-Up on Hipersep^® Pilot

For the outstanding efficiency and scalability, high-performance liquid chromatography (HPLC) has been widely used for purification of high-quality APIs and intermediates in the pharmaceutical industry.

Pfizer announces positive top-line results from JADE TEEN trial of abrocitinib in adolescents with moderate-to-severe atopic dermatitis

Pfizer announced positive top-line results from the Phase 3 JADE TEEN study of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients 12 to <18 years of age with moderate to severe atopic dermatitis (AD) who were also on background topical therapy. Both doses of abrocitinib met the co-primary endpoints and were generally well tolerated.

Lyvgen announces clinical trial collaboration with MSD

Lyvgen, a biopharmaceutical company focused on developing innovative immuno-oncology therapeutics, announces that it has entered into a clinical trial collaboration agreement with a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A., known as MSD outside of the U.S. and Canada.

Bristol Myers Squibb, UbiVac to assess combination immunotherapy for advanced triple-negative breast cancer

UbiVac has announced clinical trial collaboration Bristol Myers Squibb (BMS) on the combination immunotherapy for advanced triple negative breast cancer.

Relief Therapeutics and NeuroRx expand clinical trial of RLF-100 to all patients with critical Covid-19 and respiratory failure

RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” and its U.S. partner, NeuroRx, Inc. today announced that the phase 2/3 clinical trial evaluating RLF-100 as a treatment for Critical COVID-19 with Respiratory Failure has been expanded to include patients receiving high flow oxygen and noninvasive ventilation (CPAP), in addition to those on ventilators. RLF-100 (Aviptadil) is a patented formulation of synthetic human Vasoactive Intestinal Peptide (VIP), which has been granted Orphan Drug Designation by the US FDA in Acute Respiratory Distress Syndrome and chronic lung diseases.

Eli Lilly’s partner Junshi doses first patient in Covid-19 trial with JS016 investigational medicine

Eli Lilly has announced the commencement of a phase 1 study for its second potential Covid-19 antibody treatment.